ClinicalTrials.gg
CompletedNCT02720692Updated Jun 22, 2023Results posted

Evaluation of N1539 Following Major Surgery

A Phase 3 interventional study of N1539 and Intravenous Placebo in Pain, Post-operative, sponsored by Baudax Bio. Completed at 32 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Baudax Bio · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
722
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing meloxicam in Pain, Postoperative — 2 open to participants now, 3 under way, none of them phase 3. Meloxicam · Pain, Postoperative.

Enrollment
Largest of 24
722 · median 112
Started
2016
with 2 others
Phase 3
9 of 24
none open now
Registered
5th of 24
by date
Lead sponsor
7 of 24
Baudax Bio

Among the 24 studies testing meloxicam in Pain, Postoperative, this one has the largest enrollment, is one of 3 that started in 2016, is one of 9 in phase 3, and was the 5th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 24 studies testing meloxicam in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About meloxicam

Meloxicam: first FDA approval 2000 (MOBIC), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing meloxicam in Pain, Postoperative, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of N1539 in a variety of post-surgical conditions.

03

Conditions studied

  • Pain, Post-operative

Keywords

  • Pain
  • Analgesia
  • N1539
  • Phase 3
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily provide written .
  • Male or female between 18 and 80 years of age, inclusive.
  • Be planning to undergo major elective surgery, and be expected to require intravenous analgesia and remain in an inpatient setting for at least 24-48 hours and are expected to receive at least two study doses.
  • Female subjects are eligible only if all the following apply:

    • Not pregnant;
    • Not breastfeeding;
    • Not able to become pregnant;
    • Not planning to become pregnant during the study or 28 day follow up;
    • Commit to the use of an acceptable form of for the duration of the study.
  • Have a ≤40 kg/m2
  • Be able to understand the study procedures, comply with all study procedures, and agree to participate in the study program.
  • For oncology cases, have a confirmed diagnosis of a primary solid tumor, affecting any one of the following organs: breast, skin, colon, prostate, uterus, ovaries, urethra, penis, or vulva; AND based on clinical, laboratory, radiologic, pathologic, and surgical findings, the tumor is confined to the primary organ, without evidence of local, regional or distal spread; AND have a performance status such that they are able to carry on normal activities of daily life without limitations.

Exclusion criteria

Exclusion Criteria:

  • Have a known allergy to meloxicam or any of N1539, aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs).
  • Be scheduled to undergo cranial surgery, open heart procedure, any type of coronary artery bypass graft, organ transplant, or any other surgical procedure in which NSAIDs are .
  • Planned or actual admission to the intensive care unit at any time during study participation.
  • Have laboratory abnormalities.
  • Have a history of myocardial infarction within the preceding 12 months.
  • Have history of , or or C.
  • Have a history or clinical manifestations of significant renal, hepatic, cardiovascular, metabolic, neurologic, psychiatric, respiratory, or other condition that would preclude participation in the study.
  • Have active or recent (within 6 months) gastrointestinal ulceration or bleeding
  • Have a known bleeding disorder which may be worsened with the administration of a NSAID.
  • Have evidence of a clinically significant 12 lead abnormality.
  • Have a history of alcohol abuse (regularly drinks > 4 units of alcohol per day; 8 oz. beer, 3 oz. wine, 1 oz. spirits) or a history of prescription/illicit drug abuse within the past 5 years.
  • Have positive results on the urine drug screen for cocaine or PCP or alcohol breath test indicative of illicit drug or alcohol abuse.
  • Unable to discontinue medications, that have not been at a stable dose for at least 14 days prior to the scheduled surgical procedure, within 5 half-lives of the specific prior medication (or, if half-life is not known, within 48 hours) before dosing with study medication.
  • Be unable to discontinue herbal medications at least 7 days prior to surgery through last dose of study medication.
  • Be receiving lithium, or a combination of furosemide with either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker
  • Be currently receiving treatment with oral meloxicam (Mobic®) or other NSAID within 7 days prior to surgery.
  • Have received any product within 30 days before dosing with study medication.
  • Have previously received N1539 in clinical trials, or had major surgery in the last 3 months that would interfere with study assessments.
  • Have undergone or be expected to undergo radiation therapy, chemotherapy, or other biological therapy for cancer treatment, within 60 days prior to screening, through the last study visit, approximately 30 days after dosing.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
722 participants (actual)

Study arms

  • Experimental
    N1539 30mg

    N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 7 doses.

    Drug: N1539

  • Placebo comparator
    IV Placebo

    IV Placebo every 24 hours for up to 7 doses.

    Drug: Intravenous Placebo

Interventions

  • DrugN1539

    Also known as: Intravenous meloxicam

  • DrugIntravenous Placebo
06

What researchers measure

Primary outcomes

  1. Number of Subjects With Adverse Events

    Number of subjects reporting 1 or more treatment-emergent adverse events

    Time frame: 28 Days

Secondary outcomes

  1. Investigator Satisfaction With Surgical Wound Healing

    Investigators assessed their satisfaction with the healing of the surgical wound according to an 11-point numeric rating scale (0-10) where a score of 0 was completely unsatisfied (worse outcome), and a score of 10 was completely satisfied (better outcome).

    Time frame: Up to 7 days after last study dose

  2. Postoperative Opioid Use

    Postoperative opioid use was measured throughout the inpatient phase and converted to the total IV morphine equivalent dose

    Time frame: Up to 7 days

07

Results

Posted May 25, 2023

Participant flow

Participant flow — Overall Study
MilestoneN1539 30 mgIV Placebo
Started539183
Treated538183
Completed treatment519177
Completed526180
Not completed133
Withdrew: Withdrawal by subject30
Withdrew: Physician decision10
Withdrew: Lost to follow-up83
Withdrew: Subject unable to return for visit10

Outcome measures

PrimaryNumber of Subjects With Adverse Events

Number of subjects reporting 1 or more treatment-emergent adverse events

Time frame:
28 Days
Reported as:
Count of participants · Participants
Number of Subjects With Adverse Events
ParticipantsN1539 30 mgIV Placebo
Number of Subjects With Adverse Events339119
SecondaryInvestigator Satisfaction With Surgical Wound Healing

Investigators assessed their satisfaction with the healing of the surgical wound according to an 11-point numeric rating scale (0-10) where a score of 0 was completely unsatisfied (worse outcome), and a score of 10 was completely satisfied (better outcome).

Time frame:
Up to 7 days after last study dose
Reported as:
Mean · score on a scale
Investigator Satisfaction With Surgical Wound Healing
score on a scaleN1539 30 mgIV Placebo
One day after last study dose/Discharge9.5 ± 0.889.4 ± 0.97
7 Days after last study dose9.3 ± 1.189.4 ± 0.86
SecondaryPostoperative Opioid Use

Postoperative opioid use was measured throughout the inpatient phase and converted to the total IV morphine equivalent dose

Time frame:
Up to 7 days
Reported as:
Mean · mg (IV Morphine Equivalent Dose)
Postoperative Opioid Use
mg (IV Morphine Equivalent Dose)N1539 30 mgIV Placebo
Day 1 (Hour 0-24)17.0 ± 22.1021.8 ± 24.70
Day 2 (Hour 24-48)8.6 ± 19.1511.3 ± 21.82
Day 3 (Hour 48-72)4.1 ± 16.606.2 ± 21.83
Day 1-2 (Hour 0-48)25.3 ± 36.9632.7 ± 41.44
Day 1-3 (Hour 0-72)27.4 ± 44.6735.9 ± 52.77
During Treatment28.8 ± 57.3937.5 ± 66.06
Statistical analysis
  • N1539 30 mg vs IV Placebo · ANCOVA · p = <0.05 (P\<0.05 applies to Day 1 (0-24 Hours; p=0.0033), Days 1-2 (0-48 Hours; p=0.0077), and Days 1-3 (0-72 Hours; p=0.0152).)

Adverse events

Collected over AE data were collected from the time of first study dose, through the last study contact, 28 days following the last study dose.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
N1539 30 mg0/538 (0%)14/538 (2.6%)227/538 (42.2%)
IV Placebo0/183 (0%)10/183 (5.5%)85/183 (46.4%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventN1539 30 mgIV Placebo
Post procedural pulmonary embolismInjury, poisoning and procedural complications3/5380/183
Coronary artery diseaseCardiac disorders0/5381/183
Jejunal stenosisGastrointestinal disorders0/5381/183
NauseaGastrointestinal disorders0/5381/183
Hepatocellular injuryHepatobiliary disorders0/5381/183
Abdominal abscessInfections and infestations0/5381/183
Postoperative abscessInfections and infestations0/5381/183
Anastomotic ulcerInjury, poisoning and procedural complications0/5381/183
Incisional herniaInjury, poisoning and procedural complications0/5381/183
Postoperative ileusInjury, poisoning and procedural complications1/5381/183
Most frequent other events
Showing 10 of 11
Most frequent other events
EventN1539 30 mgIV Placebo
NauseaGastrointestinal disorders123/53850/183
ConstipationGastrointestinal disorders51/53817/183
VomitingGastrointestinal disorders27/53814/183
HeadacheNervous system disorders20/53812/183
PruritusSkin and subcutaneous tissue disorders21/53810/183
Gamma-glutamyltransferase increasedInvestigations21/5385/183
Alanine aminotransferase increasedInvestigations11/5387/183
DizzinessNervous system disorders15/5387/183
AnaemiaBlood and lymphatic system disorders18/5384/183
InsomniaPsychiatric disorders9/5386/183

Baseline characteristics

All Treated Subjects (Safety Analysis Set)

Age, Categorical
Age, Categorical(Participants)N1539 30 mgIV PlaceboTotal
<=18 years202
Between 18 and 65 years416140556
>=65 years12043163
Age, Continuous
Age, Continuous(years)N1539 30 mgIV PlaceboTotal
Mean52.9 ± 13.5653.0 ± 13.7753.0 ± 13.60
Sex: Female, Male
Sex: Female, Male(Participants)N1539 30 mgIV PlaceboTotal
Female315113428
Male22370293
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)N1539 30 mgIV PlaceboTotal
Hispanic or Latino7629105
Not Hispanic or Latino462154616
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)N1539 30 mgIV PlaceboTotal
American Indian or Alaska Native101
Asian7411
Native Hawaiian or Other Pacific Islander202
Black or African American682189
White459155614
More than one race134
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)N1539 30 mgIV PlaceboTotal
United States502168670
Canada538
New Zealand8210
Australia231033
Advanced Age (>65) with Impaired Renal Function (GFR<90)
Advanced Age (>65) with Impaired Renal Function (GFR<90)(Participants)N1539 30 mgIV PlaceboTotal
Count of participants8831119
Surgery Site/Type
Surgery Site/Type(Participants)N1539 30 mgIV PlaceboTotal
Orthopedic27393366
Abdominal/Pelvic25487341
Spinal10313
Other101
08

Study locations

32 sites
  • Florence, Alabama 35630, United States
  • Montgomery, Alabama 36116, United States
  • Sheffield, Alabama 35660, United States
  • Gilbert, Arizona 85295, United States
  • Phoenix, Arizona 85023, United States
  • Anaheim, California 92801, United States
  • Bakersfield, California 93301, United States
  • Miami, Florida 33136, United States
  • Tamarac, Florida 33321, United States
  • Tampa, Florida 33605, United States
  • Chicago, Illinois 60612, United States
  • Great Falls, Montana 59405, United States
  • Cleveland, Ohio 44111, United States
  • Columbus, Ohio 43210, United States
  • Tyrone, Pennsylvania 16686, United States
  • Hendersonville, Tennessee 37075, United States
  • Houston, Texas 77004, United States
  • Houston, Texas 77030, United States
  • San Antonio, Texas 78229, United States
  • Salt Lake City, Utah 84124, United States
  • Chermside, Queensland 4032, Australia
  • Kippa-Ring, Queensland 4021, Australia
  • Southport, Queensland 4215, Australia
  • Richmond, Victoria 3121, Australia
  • Halifax, Nova Scotia B#H2Y, Canada
  • Kingston, Ontario K7L2V7, Canada
  • Toronto, Ontario M5T2S8, Canada
  • Montreal, Quebec H1T2M4, Canada
  • Montreal, Quebec H4A3J1, Canada
  • Auckland, New Zealand
  • Christchurch, 8024, New Zealand
  • Hamilton, 3206, New Zealand
09

References and documents

Publications

  • Sharpe KP, Berkowitz R, Tyndall WA, Boyer D, McCallum SW, Mack RJ, Du W. Safety, Tolerability, and Effect on Opioid Use of Meloxicam IV Following Orthopedic Surgery. J Pain Res. 2020 Jan 21;13:221-229. doi: 10.2147/JPR.S216219. eCollection 2020. PubMed 32021411 ↗
  • Bergese SD, Melson TI, Candiotti KA, Ayad SS, Mack RJ, McCallum SW, Du W, Gomez A, Marcet JE. A Phase 3, Randomized, Placebo-Controlled Evaluation of the Safety of Intravenous Meloxicam Following Major Surgery. Clin Pharmacol Drug Dev. 2019 Nov;8(8):1062-1072. doi: 10.1002/cpdd.666. Epub 2019 Feb 20. Erratum In: Clin Pharmacol Drug Dev. 2020 Aug;9(6):774. doi: 10.1002/cpdd.854. PubMed 30786162 ↗
  • Viscusi ER, Gan TJ, Bergese S, Singla N, Mack RJ, McCallum SW, Du W, Hobson S. Intravenous meloxicam for the treatment of moderate to severe acute pain: a pooled analysis of safety and opioid-reducing effects. Reg Anesth Pain Med. 2019 Mar;44(3):360-368. doi: 10.1136/rapm-2018-100184. Epub 2019 Feb 7. PubMed 30737315 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Mar 2017, 12 months.

Results were first posted in May 2023, 6 years 2 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 12 months is close to that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2016
First posted
Mar 28, 2016
StartActual
Mar 2016
Primary completionActual
Mar 2017
CompletionActual
May 2017
Results first posted
May 25, 2023
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02720692
Lead sponsor
Baudax Bio
Responsible party
Sponsor
First posted
Mar 28, 2016
Start date
Mar 2016
Primary completion
Mar 2017
Completion
May 2017
Results posted
May 25, 2023
Last update
Jun 22, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion